Results 101 to 110 of about 481,621 (347)

A Well-Defined {[(PhCH2O)2P(CH3)2CHNCH(CH3)2]2PdCl2} Complex Catalyzed Hiyama Coupling of Aryl Bromides with Arylsilanes

open access: yesMolecules, 2016
A palladium (II) complex {[(PhCH2O)2P(CH3)2CHNCH(CH3)2]2PdCl2} catalyzed Hiyama cross-coupling reaction between aryl bromides and arylsilanes has been developed.
Mengping Guo   +4 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Synthesis and characterization of dioxidomolybdenum(VI) complexes with thiosemicarbazone ligands [PDF]

open access: yes, 2014
The chemistry of thiosemicarbazone complexes of transition metals has been the subject of attention, primarily because of overgrowing biological properties. These activities have been correlated with their metal-chelating abilities and reductive capacity.
., Shweta
core  

From 18- to 20-electron ferrocene derivatives via ligand coordination

open access: yesNature Communications
The 18-electron rule is a fundamental rule in coordination chemistry on which several revolutionary discoveries in catalysis and materials science are founded.
Satoshi Takebayashi   +7 more
doaj   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

open access: yesMolecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak   +8 more
wiley   +1 more source

Schiff bases and their possible therapeutic applications: A review

open access: yesResults in Chemistry
Schiff base (SB) represents a category of organic compounds in which a nitrogen atom with a double bond maintains its stereochemistry. The long history of Schiff base has been fascinating chemists to explore its new dimension by generating optimal ...
Nidhi   +5 more
doaj   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

An antibacterial agent based on diamine conjugated thenil Schiff Base: synthesis, crystal structure, and activity studies

open access: yesDiscover Applied Sciences
A unique asymmetric Schiff base compound originated from thenil underwent synthesis and characterization via analytical and spectroscopic methods. The compound was obtained through thenil (Di-2-thienylethanedione) and 1, 2-diaminotoluene reaction using ...
Nidhi   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy